AUG 21·SEC EDGARLow
Gloria Melanie sold $135K of IMVT
Gloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$IMVT
Immunovant, Inc.
Price · $IMVTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IMVT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $135K 1 txs
Gloria Melanie1× · $135K
10b5-1 share of filings0%
Top stories · $IMVTMore →
AUG 14·simplywall.st
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype
Immunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
AUG 6·SEC EDGAR 8-K
Immunovant, Inc. (IMVT): Results of Operations and Financial Condition
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory dem
IMVT sentiment & insider activity
Recent IMVT coverage spans insider activity, financial news and earnings.
In the last 30 days, IMVT insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($135K). The most active reporter was Gloria Melanie, Chief Operating Officer, with 1 filing.
What's driving IMVT
Minor dilution of insider ownership may slightly pressure the stock.
Near-term sentiment is likely driven by the next IMVT-1402 pivotal readouts, while the wider loss and potential dilution keep downside risk elevated.
The filing updates cash runway and R&D burn while reiterating IMVT-1402 development timing, which can shift biotech risk appetite and near-term valuation expectations.
Routine insider open-market sale by the CFO, with no 10b5-1 plan cited, may slightly affect near-term sentiment but is not a fundamental catalyst.
This is a routine insider open-market sale with no 10b5-1 plan disclosed; it may slightly affect sentiment but is not a fundamental catalyst.
alphai scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IMVT
Score
Gloria Melanie sold $135K of IMVT
Gloria Melanie (Chief Operating Officer) sold 3,056 shares of Immunovant, Inc. (IMVT) at $44.16 ($0.13M total) on 2026-08-20.
1 min readWhy Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype
Immunovant (IMVT) reported wider Q1 2026 net loss of $153.22M, or $0.75/share, versus $120.61M, or $0.71/share a year earlier. The company cited upcoming pivotal data readouts and potential launches, alongside cash inflows tied to a Moderna settlement. The article also references analyst projections for 2029 revenue and earnings.
5 min readImmunovant, Inc. (IMVT): Results of Operations and Financial Condition
Immunovant, Inc. (IMVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 • All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory dem
4 min readGirao Tiago sold $263K of IMVT
Girao Tiago (Chief Financial Officer) sold 6,798 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.26M total) on 2026-07-23.
2 min readStout Jay S sold $111K of IMVT
Stout Jay S (Chief Technology Officer) sold 2,857 shares of Immunovant, Inc. (IMVT) at $38.69 ($0.11M total) on 2026-07-23.
1 min readStout Jay S sold $138K of IMVT
Stout Jay S (Chief Technology Officer) sold 3,487 shares of Immunovant, Inc. (IMVT) at an average of $39.55 ($39.53–$39.99, $0.14M total) across 4 trades on 2026-07-08.
1 min readVenker Eric sold $119K of IMVT
Venker Eric (Chief Executive Officer) sold 3,092 shares of Immunovant, Inc. (IMVT) at $38.48 ($0.12M total) on 2026-07-02.
1 min readVenker Eric sold (to issuer) $3.3M of IMVT
Venker Eric (Chief Executive Officer) sold (to issuer) 86,629 shares of Immunovant, Inc. (IMVT) at $38.14 ($3.30M total) on 2026-07-01.
1 min readGloria Melanie sold $679K of IMVT
Gloria Melanie (Chief Operating Officer) sold 17,714 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.18–$38.95, $0.68M total) across 2 trades on 2026-06-26.
3 min readStout Jay S sold $1.5M of IMVT
Stout Jay S (Chief Technology Officer) sold 40,000 shares of Immunovant, Inc. (IMVT) at an average of $38.31 ($38.18–$38.94, $1.53M total) across 2 trades on 2026-06-26.
2 min read